27261525|t|The N-Methyl d-Aspartate Glutamate Receptor Antagonist Ketamine Disrupts the Functional State of the Corticothalamic Pathway
27261525|a|The non-competitive N-methyl d-aspartate glutamate receptor (NMDAR) antagonist ketamine elicits a brain state resembling high-risk states for developing psychosis and early stages of schizophrenia characterized by sensory and cognitive deficits and aberrant ongoing gamma oscillations (30-80 Hz)in cortical and subcortical structures, including the thalamus. The underlying mechanisms are unknown. The goal of the present study was to determine whether a ketamine - induced psychotic - relevant state disturbs the functional state of the corticothalamic (CT) pathway. Multisite field recordings were performed in the somatosensory CT system of the sedated rat. Baseline activity was challenged by activation of vibrissa - related prethalamic inputs. The sensory - evoked thalamic response was characterized by a short - latency (∼4 ms) prethalamic -mediated negative sharp potential and a longer latency (∼10 ms) CT -mediated negative potential. Following a single subcutaneous injection of ketamine (2.5 mg/kg), spontaneously occurring and sensory - evoked thalamic gamma oscillations increased and decreased in power, respectively. The power of the sensory -related gamma oscillations was positively correlated with both the amplitude and the area under the curve of the corresponding CT potential but not with the prethalamic potential. The present results show that the layer VI CT pathway significantly contributes in thalamic gamma oscillations, and they support the hypothesis that reduced NMDAR activation disturbs the functional state of CT and corticocortical networks.
27261525	4	54	N-Methyl d-Aspartate Glutamate Receptor Antagonist	T121	C0598695
27261525	55	63	Ketamine	T109,T121	C0022614
27261525	64	72	Disrupts	T080	C0332454
27261525	77	87	Functional	T169	C0205245
27261525	88	93	State	T169	C1442792
27261525	101	116	Corticothalamic	T023	C1184631
27261525	117	124	Pathway	T077	C1705987
27261525	129	144	non-competitive	UnknownType	C0815027
27261525	145	203	N-methyl d-aspartate glutamate receptor (NMDAR) antagonist	T121	C0598695
27261525	204	212	ketamine	T109,T121	C0022614
27261525	223	228	brain	T023	C0006104
27261525	229	234	state	T169	C1442792
27261525	246	255	high-risk	T033	C0332167
27261525	256	262	states	T169	C1442792
27261525	278	287	psychosis	T048	C0033975
27261525	292	304	early stages	T079	C2363430
27261525	308	321	schizophrenia	T048	C0036341
27261525	322	335	characterized	T052	C1880022
27261525	339	346	sensory	T047	C0748618
27261525	351	369	cognitive deficits	T048	C0009241
27261525	383	390	ongoing	T078	C0549178
27261525	391	409	gamma oscillations	T042	C0678909
27261525	423	431	cortical	T023	C0007776
27261525	436	447	subcortical	T029	C0815275
27261525	448	458	structures	T082	C0678594
27261525	474	482	thalamus	T023	C0039729
27261525	499	509	mechanisms	T169	C0441712
27261525	514	521	unknown	T080	C0439673
27261525	527	531	goal	T170	C0018017
27261525	539	546	present	T079	C0521116
27261525	547	552	study	T062	C2603343
27261525	580	588	ketamine	T109,T121	C0022614
27261525	591	598	induced	T169	C0205263
27261525	599	608	psychotic	T048	C0033975
27261525	611	619	relevant	T080	C2347946
27261525	620	625	state	T169	C1442792
27261525	626	634	disturbs	T080	C2699787
27261525	639	649	functional	T169	C0205245
27261525	650	655	state	T169	C1442792
27261525	663	678	corticothalamic	T023	C1184631
27261525	680	682	CT	T023	C1184631
27261525	684	691	pathway	T077	C1705987
27261525	693	719	Multisite field recordings	T060	C0430022
27261525	725	734	performed	T169	C0884358
27261525	742	765	somatosensory CT system	T022	C0682661
27261525	773	780	sedated	T033	C0235195
27261525	781	784	rat	T015	C0034721
27261525	786	794	Baseline	T081	C1442488
27261525	795	803	activity	T052	C0441655
27261525	822	832	activation	T052	C1879547
27261525	836	844	vibrissa	T023	C0042640
27261525	847	854	related	T080	C0439849
27261525	855	866	prethalamic	T029	C0152349
27261525	867	873	inputs	T077	C1708517
27261525	879	886	sensory	T080	C0445254
27261525	889	913	evoked thalamic response	T042	C0015214
27261525	918	931	characterized	T052	C1880022
27261525	937	942	short	T081	C1806781
27261525	945	952	latency	T080	C0205275
27261525	961	972	prethalamic	T029	C0152349
27261525	983	991	negative	T080	C2825491
27261525	998	1007	potential	T043	C0001272
27261525	1014	1020	longer	T080	C0205166
27261525	1021	1028	latency	T080	C0205275
27261525	1038	1040	CT	T023	C1184631
27261525	1051	1059	negative	T080	C2825491
27261525	1060	1069	potential	T043	C0001272
27261525	1083	1089	single	T081	C0205171
27261525	1090	1112	subcutaneous injection	T169	C0021499
27261525	1116	1124	ketamine	T109,T121	C0022614
27261525	1138	1151	spontaneously	T169	C0205359
27261525	1166	1173	sensory	T080	C0445254
27261525	1176	1210	evoked thalamic gamma oscillations	T042	C0015214
27261525	1211	1220	increased	T081	C0205217
27261525	1225	1234	decreased	T081	C0205216
27261525	1238	1243	power	T081	C3854080
27261525	1263	1268	power	T081	C3854080
27261525	1276	1283	sensory	T080	C0445254
27261525	1293	1311	gamma oscillations	T042	C0678909
27261525	1316	1326	positively	T033	C1446409
27261525	1327	1337	correlated	T080	C1707520
27261525	1352	1361	amplitude	T082	C2346753
27261525	1370	1390	area under the curve	T081	C0376690
27261525	1412	1414	CT	T023	C1184631
27261525	1415	1424	potential	T043	C0001272
27261525	1442	1453	prethalamic	T029	C0152349
27261525	1454	1463	potential	T043	C0001272
27261525	1469	1476	present	T079	C0521116
27261525	1477	1484	results	T169	C1274040
27261525	1499	1507	layer VI	T023	C2322689
27261525	1508	1510	CT	T023	C1184631
27261525	1511	1518	pathway	T077	C1705987
27261525	1533	1544	contributes	T052	C1880177
27261525	1548	1556	thalamic	T023	C0039729
27261525	1557	1575	gamma oscillations	T042	C0678909
27261525	1598	1608	hypothesis	T078	C1512571
27261525	1614	1621	reduced	T080	C0392756
27261525	1622	1627	NMDAR	T116,T192	C0080093
27261525	1628	1638	activation	T043	C1514758
27261525	1639	1647	disturbs	T080	C2699787
27261525	1652	1662	functional	T169	C0205245
27261525	1663	1668	state	T169	C1442792
27261525	1672	1674	CT	T023	C1184631
27261525	1679	1694	corticocortical	T023	C0007776
27261525	1695	1703	networks	T040	C0598941